Paycom Software Inc vs Sana Biotechnology Inc — how do they compare? Paycom Software Inc trades at $139 (market cap $6.72B), while Sana Biotechnology Inc trades at $3.13 (market cap $879.40M). The key difference: Paycom Software Inc is far larger — about 7.6× Sana Biotechnology Inc's market cap, and Paycom Software Inc pays a 1.04% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| PAYC | SANA | |
|---|---|---|
Market Cap | $6.72B | $879.40M |
Sector | Technology | Health |
52-Week High | $238.80 | $5.92 |
52-Week Low | $113.59 | $2.68 |
Enterprise Value | $7.33B | $853.59M |
Dividend Yield | 1.04% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SANA Biotechnology trades at $3.14, down 0.32% with a bearish technical signal. The company shows negative profitability metrics with ROE at -147.41% and net income of -$244.17M for 2025, though cash burn is projected to improve significantly in 2026. Recent positive developments include NEJM publication of groundbreaking diabetes data and multiple conference presentations highlighting clinical progress.
While analyst sentiment remains strongly bullish (82% buy ratings), the stock faces fundamental challenges with significant losses and high P/B ratio of 7.33. Investment opportunity lies in clinical pipeline advancements, but risks include ongoing cash burn and execution challenges in bringing therapies to market.
Trailing returns across standard periods
Paycom is a fast-growing provider of payroll and human capital management, or HCM, software primarily targeting clients with 50-10,000 employees in the United States. Paycom was established in 1998 and services about 18,000 clients as of 2021, based on parent company grouping. Alongside its core payroll software, Paycom offers various HCM add-on modules, including time and attendance, talent management, and benefits administration.
Read more on PAYC →Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →